Inês Martins, PhD,  managing science editor—

Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by Inês Martins

AMX0035 Significantly Slows Disease Progression in ALS, Phase 2 Study Shows

Updated results from the CENTAUR Phase 2 trial show that Amylyx‘s investigational oral treatment, AMX0035, significantly slowed progression in treated amyotrophic lateral sclerosis (ALS) patients with rapidly advancing disease compared to those given a placebo. The trial reached its primary goal shortly after its final patient examination in September. Data show…

Large ALS Data Analysis Reveals Common Genetic Cause of Disease

Researchers have found that mutations in the NEK1 gene are the most common genetic causes of amyotrophic lateral sclerosis (ALS), accounting for 3 percent of North American and European ALS patients, both sporadic and familial. The study, “NEK1 variants confer susceptibility to amyotrophic lateral sclerosis,” published in…

Neurodegenerative Diseases May Be Prevented by Autophagy Assisting Plant Compounds

Researchers at the University of Occupational and Environmental Health in Japan, reviewed advances for using natural plant compounds to regulate autophagy, a process in the development of many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, muscular atrophies, spinocerebellar ataxia 3, and amyotrophic lateral sclerosis (ALS). The review “Natural compounds preventing…

Cerebrospinal Fluid of ALS Patients Has Reduced Levels of Anti-Inflammatory Protein, Revealing Potential New Therapeutic Target

Researchers from the Institute of Drug Research at the The Hebrew University in Israel have revealed that patients with amyotrophic lateral sclerosis (ALS) have low levels of the anti-inflammatory protein alpha-1-antitrypsin (AAT) in their cerebrospinal fluid (CSF). The findings have been published in the Journal of Neuroinflammation in the study…